Share on StockTwits

Acura Pharmaceuticals (NASDAQ:ACUR) Director William G. Skelly unloaded 2,900 shares of Acura Pharmaceuticals stock in a transaction dated Wednesday, May 14th. The shares were sold at an average price of $1.21, for a total value of $3,509.00. Following the completion of the transaction, the director now directly owns 14,600 shares in the company, valued at approximately $17,666. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Shares of Acura Pharmaceuticals (NASDAQ:ACUR) opened at 1.13 on Friday. Acura Pharmaceuticals has a one year low of $1.08 and a one year high of $2.59. The stock’s 50-day moving average is $1.33 and its 200-day moving average is $1.6. The company’s market cap is $55.2 million.

Acura Pharmaceuticals (NASDAQ:ACUR) last announced its earnings results on Monday, May 5th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by $0.03. On average, analysts predict that Acura Pharmaceuticals will post $-0.31 earnings per share for the current fiscal year.

Several analysts have recently commented on the stock. Analysts at MLV & Co
cut their price target on shares of Acura Pharmaceuticals from $2.25 to $2.00 in a research note on Friday, May 9th.

Acura Pharmaceuticals, Inc, is a specialty pharmaceutical company engaged in the research, development and commercialization of products focused on addressing medication abuse and misuse, utilizing its Aversion and Impede Technologies.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.